Semaglutide for Weight Loss: What the SURMOUNT-5 Results Mean for Northwest Louisiana Patients For the first time, a major clinical trial put tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) head to head in people with obesity who do not have diabetes, and the results landed in the New England Journal of Medicine in May 2025.[1] The short answer: tirzepatide produced significantly more weight loss
Heres what to have on your radar, how to manage common complications, and when to alert your provider
doi: 10.3945/jn.113.174615 8 DaviesMJArodaVRCollinsBSGabbayRAGreenJMaruthurNMet al
Measuring body composition (fat versus lean mass) should become routine in the management of patients on GLP-1 medications. The Takeaway While GLP-1 medications are effective for weight loss, rapid weight reduction can lead to significant loss of fat-free mass, including muscle
The FDA guidelines (for women, which clinicians also follow for men) say no more than one dose in 24 hours, and no more than 8 doses per month